期刊名称：BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology contains papers and reports on all aspects of drug action in humans: invited review articles, original papers, short communications and correspondence. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. Proceedings of the meetings of the Clinical Section of the British Pharmacological Society are published in abstract form, and supplements containing information on new methods, new drugs and new approaches to treatment are supplied free of charge.
Abstracting and Indexing Information
Abstracts in Anthropology (Baywood Publishing)
Academic Search (EBSCO)
Academic Search Elite (EBSCO)
Academic Search Premier (EBSCO)
Biological Abstracts® (Thomson ISI)
BIOSIS Previews® (Thomson ISI)
CAB Abstracts® (CABI)
CAB HEALTH (CABI)
CABDirect (CABI)
CABS (Current Awareness in Biological Sciences)
CAS: Chemical Abstracts Service (CAS)
CSA Biological Sciences Database (CSA/CIG)
CSA Environmental Sciences & Pollution Management Database (CSA/CIG)
Current Abstracts (EBSCO)
Current Contents®/Clinical Medicine (Thomson ISI)
Embase/Excerpta medica (Elsevier)
EORTC Database (European Organisation for Research and Treatment of Cancer)
Health Source Nursing/Academic (EBSCO)
IBIDS: International Bibliographic Information on Dietary Supplements ()
International Pharmaceutical Abstracts (Thomson Scientific)
Journal Citation Reports/Science Edition (Thomson ISI)
LEIsure Tourism Database (LEIsure)
Leisure, Recreation and Tourism Abstracts (CABI)
MEDLINE/PubMed (NLM)
Neurosciences Abstracts (CSA/CIG)
Protozoological Abstracts (Elsevier)
Reference Update (Thomson ISI)
Research Alert® (Thomson ISI)
Review of Medical & Veterinary Mycology (CABI)
Sci Search® (Thomson ISI)
Science Citation Index Expanded (also known as SciSearch®)
Science Citation Index® (Thomson ISI)
VINITI (All-Russian Institute of Science & Technological Information)
|
|
Instructions to Authors
The Journal will publish original papers and reviews. Other forms of articles will be considered for publication under various headings, such as Methods, Topics in Therapeutics, Commentary, Opinion, Meeting Report, Cochrane reviews, and Case Reports. Although the Journal welcomes papers on all aspects of pharmacogenetics, comparisons of mutant/variant allelic frequencies in different ethnic populations will not be considered for publication unless the variant genes have an association with a particular disease or add other new information of potential relevance to pharmacotherapy.
Authors who plan to submit such an article should contact the Editorial Office in advance for advice on the suitability of the article proposed.
Once you have read the Submission Guidelines below, please go to ScholarOne Manuscripts (http://mc.manuscriptcentral.com/bcp) to submit your manuscript.
Preparing and submitting a manuscript
A recent issue of the Journal is a good guide to style. Manuscript documents should be typed in double spacing and should be page numbered. A separate title page should be included (see below). The author to whom all correspondence will be sent during the submission phase (the submitting author) need not be the same as the corresponding author listed on the final paper.
Please submit your manuscript online at http://mc.manuscriptcentral.com/bcp. Submissions can be uploaded as Rich Text Format (rtf) files plus separate figure files (gif, jpg, bmp, tif, pic) or as a Word document (including artwork).
The main text file must contain the entire manuscript, including title page, abstract, text, references, tables, figure legends, and (for Word file submissions) figures. Pdf and ppt files are not accepted.
Manuscripts for rtf submission should contain all of the above but no figures, which should be submitted separately. Figure tags should be included in the file.
Manuscripts in rtf format should not contain word processor styles (for example bold, italics, justification).
For more information about online submission, please read the detailed instructions at http://mc.manuscriptcentral.com/bcp Author Centre or email the Editorial Assistant at BJCPedoffice@wiley.com.
If you cannot submit online, or have any difficulties in doing so, please contact the Editorial Assistant.
Reviewers
Authors are asked to facilitate the review process by providing the names and email addresses of two suitable reviewers, on the understanding that the Editors are not bound by any such nomination.
Accompanying documents
Licence to publish
A completed Exclusive Licence form must be included with the submitted manuscript. This form is available on http://mc.manuscriptcentral.com/bcp under 'instructions and forms'.
Originality and agreement of all authors
Papers will not be approved for review unless accompanied by a statement, in the covering letter, that they have not been, and will not be published, in whole, or in part, in any other journal, and that all the authors have agreed to the contents of the manuscript in its submitted form; each author should sign such a statement. If authors have a problem in contacting a co-author for approval, this should be discussed with the Editor.
However, if there is any overlap between a submitted manuscript of an original paper and a paper that is being submitted elsewhere, the submitting author should draw this to the attention of the Editors in the submission covering letter and enclose a copy of the relevant submitted paper(s).
If there is any overlap with a paper that has already been published elsewhere (including online publication), including use of the same subjects or repetition of any data, that paper should be referred to and cited in full.
Competing interests
Authors should provide a statement of any competing interests within the submitted manuscript. We will not reject a paper simply because of a competing interest, but we will publish a statement of declared interests.
A declaration of competing interest form (similar to that used by the British Medical Journal (BMJ)) will need to be signed by all authors before publication can proceed. This form is available on http://mc.manuscriptcentral.com/bcp under 'instructions and forms'.
Using copyrighted material
It is the author’s responsibility to obtain permission to use copyrighted material, including print and electronic forms, in a paper, and to acknowledge the source of the material.
English language
Papers must be written in clear, concise UK English. Avoid jargon and neologisms. Regrettably, the Journal is unable to undertake major corrections to language, which is the responsibility of the author.
Authors whose first language is not English are advised to have their papers checked before submission, as manuscripts may have to be rejected if they are not written in clear English, whatever their scientific merit.
For more information on pre-acceptance English-language editing, please visit http://authorservices.wiley.com/bauthor/english_language.asp.
Note that Japanese fonts must not be used in the creation of files; the standard Adobe Acrobat program is not compatible with these fonts.
Original papers
Original papers should generally be divided into the following sections: title page, structured summary, introduction, methods, results, discussion, acknowledgements, references, tables, legends to figures, and figures.
Short Reports
Brief original reports will be considered. The length, including references, should not exceed 1500 words, with a structured abstract of 100 words and not more than two figures or tables, or one of each.
'What this paper adds statement' - Authors should supply a brief description of what their original paper or short report adds to the literature. This text should be placed before the structured abstract. It should be divided into two sections, each containing up to three short sentences.
What is already known about this subject - In up to three short sentences summarize the state of scientific knowledge on this subject before you did your study and say why this study needed to be done.
What this study adds - In up to three short sentences give a simple answer to the question 'What do we now know as a result of this study that we did not know before?' Be succinct and specific.
Review articles
Review articles on a wide range of topics appear regularly in the Journal. Articles may be unsolicited, or may be commissioned by the Reviews Editor. Either kind may be single papers or, by prior agreement with the Editor, part of a themed series. Contributors are welcome to submit single articles directly, or may wish to discuss their proposal in advance. Most reviews should be between 2500 and 3000 words, should be fully referenced, and will undergo peer review. Each review should include a summary and will be subject to the other requirements of an original paper.
From time to time the Journal will publish themed issues, including review articles and related original papers. Authors who want to suggest a theme for a special issue should contact the Editor-in-Chief.
Systematic reviews
The Journal will publish systematic reviews and will consider for publication revised versions of reviews that have already appeared as Cochrane reviews. Cochrane reviews submitted by this process will not normally be sent out for external peer-review again, but will be subjected to expedited internal peer review by an Executive Editor. In order to expedite this process, the submission should include:
1) a cover letter from the Review Group that endorsed the Cochrane review;
2) copies of two external referees' assessments of the Cochrane review, with information about how the referees’ comments have been addressed.
The review should have a word count of about 2000 words. We recognize that some methodological information (such as detailed search strategies and lists of excluded studies) will not fit within this word limit, and authors should direct interested readers to the relevant sections of the full Cochrane review.
The manuscript should provide a concise account of the methods used, and concentrate on highlighting key aspects of interest and relevance to clinical pharmacologists, under the following headings: Structured abstract, Objectives, Methods, Results, Discussion, and Conclusion.
Objectives What was the reason for the review? The strengths and weaknesses of the existing literature should be briefly reviewed.
Methods Study selection (search strategy, type of intervention/exposure, types of studies included, types of outcomes, types of participants); data extraction and synthesis (statistical techniques and use of a quality assessment tool, if any).
Results The key characteristics of the included studies and the main outcome measures; discuss variation within and between studies.
Discussion Compare the findings to existing knowledge; outline the limitations of the review.
Conclusion Summarize the key findings and the implications for clinical pharmacology and/or practical drug therapy.
Letters to the Editors
Comments on previously published papers, items of topical interest, and brief original communications will be considered under this heading. The length, including references, should not exceed 800 words, plus one figure or table. The letter should not be divided into sections.
Case reports (to be submitted as Letters to the Editors)
The Journal will consider case reports (for example adverse drug reactions or interactions) that include some novel aspect of drug action in man (for example a new adverse reaction or one that gives insight into a mechanism or method of management). Such reports may include single cases or short case series. Notes and guidelines on the format for publishing such reports, including a structured summary, will be found at [http://bmj.bmjjournals.com/cgi/content/full/326/7403/1346/DC1].
Terminology
Stereoisomers
When a drug can exist as stereoisomers or diastereomers (for example geometrical isomers), the form of compound studied must be designated as follows in the methods section.
In the case of racemates the prefix rac- should precede the drug name (for example rac-propranolol).
When possible the absolute configuration of enantiomers should be indicated (for example (S)-warfarin).
Similarly, geometrical isomerism should be indicated by the prefixes Z/E or cis/trans. When appropriate, the interpretation of data obtained using mixtures of isomers should take account of stereochemical aspects.
Drug names
All drugs should be designated by an International Non-proprietary Name (recommended, rINN, or proposed, pINN). If such a name is not available, a drug should be designated by its British Approved Name (BAN; for example hyoscyamine) or its chemical name (for example glyceryl trinitrate).
When a mixture of drugs has a combination BAN (for example co-trimoxazole, co-fluampicil), that should be used.
For brevity, a company's code name may be used, but in that case the full chemical name of structure of the drug should be given in the introduction or a reference provided that gives this information.
Units
SI units (mass or molar units) should be used. If other units are used, a conversion factor should be included in the Methods section. See [url in preparation] for more information.
Symbols
A set of standard symbols in pharmacokinetics and pharmacodynamics can be found at www.bjcp-journal.com.
Structure
Title page
The title page should include:
the title giving an informative and accurate indication of the content of the paper. It should be no longer than 150 characters, including spaces;
the names, positions, and addresses of the authors;
the name and e-mail address of the submitting author and the corresponding author, if different;
a running head of no more than 75 characters, including spaces;
keywords (these are used to identify potential referees and as indexing terms);
the word count, excluding the title page, abstract, references, tables, and figures;
the numbers of tables and figures.
Summary
The text must be preceded by a structured summary, including the following headings:
Aim(s)
Methods
Results (some numerical data, including confidence intervals on differences, when appropriate, must be included)
Conclusions
The summary should be a maximum of 250 words; abstracting services truncate summaries that are longer. It should be couched in terms that will be understood by most readers of the Journal.
Analytical methods
Authors should include details of the precision, accuracy, sensitivity, and specificity of an analytical method or refer to other publications in which the information is given.
Precision is a measure of random error, usually expressed as the coefficient of variation.
Accuracy is a measure of systematic error, also called bias; it can be expressed as the percentage difference between the result for a test sample and the reference value for that compound.
Sensitivity, also called detectability or limit of quantification, is the smallest single result that can be distinguished from zero with confidence (e.g. 3 standard deviations above baseline).
Specificity is the extent to which the method does not detect compounds other than those intended.
Statistical methods
In the Methods section statistical methods should be described clearly, with references when appropriate. Editors and referees will be particularly concerned that any study described had sufficient statistical power for its purpose; when appropriate, the power of the study and its calculation should be described in the Methods section.
In the Results section 95% confidence intervals of differences should be cited whenever possible for all important endpoints. This is particularly important when equivalence is being claimed (i.e. for non-significant comparisons). The Editors may send manuscripts to specialist statistical referees for review.
Tables
Tables should generally not have more than 85 characters to a line (counting spaces between columns as 4 characters) and certainly not more than 110 characters to a line, unless absolutely unavoidable. Each table should be typed on a separate page and be in an editable format (doc or xls).
Figures
Figures included in online submissions are for review purposes only, and should be suitable for online viewing (gif, jpg, bmp, tif, pic).
Please provide best quality figures with final accepted manuscripts at print size.
Digital files should be prepared in accordance with the instructions that will be found at http://authorservices.wiley.com/bauthor/illustration.asp. The eps format (illustrations, graphs, annotated artwork; minimum resolution 800 dpi) and tif format (micrographs, photographs; minimum resolutions 300 dpi) are recommended, although in some cases other formats can be used.
References
References should be cited using the Vancouver style (see examples below; for detailed instructions see http://www.icmje.org).
References in the manuscript text should appear as numbers in square brackets.
The reference list should show the references in numerical and not alphabetical order, and should include the names of all the authors, the full title of the article, the title of the publication (abbreviated as in Medline or PubMed), the year, the volume number, and the first and last page numbers.
References to books should include the names of the editors, the edition number, when appropriate, and the place of origin and the name of the publisher
The accuracy of the references is the responsibility of the author.
For example:
1. Johnson TN, Rostami-Hodjegan A. Tucker GT. A comparison of methods to predict drug clearance in neonates, infants and children. Br J Clin Pharmacol 2004; 57: 677-8.
2. Metters J (editor). Independent Steering Committee Report of an Independent Review of Access to the Yellow Card Scheme. London: The Stationery Office, 2004.
3. Hoffman BB, Lefkowitz RJ. Beta-adrenergic receptor antagonists. In: The Pharmacological Basis of Therapeutics, Eighth Edition, eds Gilman AG, Rail TW, Nies AS, New York: Pergamon Press, 1990: 229-43.
Acknowledgements
All support, financial or otherwise, for any work described should be acknowledged, with the exception of support from employing institutions identifiable from the title page. Authors are reminded that if they want to acknowledge the assistance of an individual, it is courteous to ask the individual’s permission to do so.
Ethical Considerations
The ethical aspects of all studies involving human subjects will be particularly noted when assessing manuscripts. The methods section should include a statement that the study was approved by an identifiable ethics committee or similar body and that the subjects consented to the study after full explanation of what was involved; it should indicate whether or not consent was obtained in writing. Details should be given of the approval of the study protocol by an ethics committee or similar body. The ethics committee that approved the protocol should be described in sufficient detail to allow the committee to be identified.
Studies using human tissues
The Methods section should contain a statement that the study was approved by an identifiable ethics committee or similar body, and that, when applicable, explicit patient consent was obtained for the use of tissue for research.
Page proofs
Proofs will be sent via e-mail as a pdf file. The e-mail server must be able to accept attachments up to 4 MB in size. Acrobat Reader will be required in order to read this file and can be downloaded (free of charge) from the following website: www.adobe.com/products/acrobat/readstep2.html. This will enable the file to be opened, read on screen, and printed out in order that corrections can be made.
Further instructions will be sent with the proof. In your absence, please arrange for a colleague to access your e-mail to retrieve the proofs.
Proofs will be posted if no e-mail address is available. Two page-proofs will be supplied, one of which should be retained by the authors. The other should be corrected immediately and returned to the Press Editor. Corrections should be kept to a minimum. Extensive changes may be charged to the author.
Once proofs have been corrected the paper will be published online. Since the online version is definitive, there will be no further opportunity for correction, even though the print version will not yet have appeared. The date of publication of the article is the date of its first appearance online as an Accepted Article.
Author Services
Author Services enables authors to track their article once it has been accepted through the production process to publication online and in print. Submitting authors can check the status of their articles online and choose to receive automated e-mails at key stages of production, so that they don’t need to contact the production editor to check progress. Visit http://authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources, including FAQs, tips on article preparation, submission, and more.
Offprints
Authors will be provided with electronic offprints of their article. Paper offprints can be ordered at prices quoted on the order form that accompanies the proofs, provided that the form is returned with the proofs. The cost is higher if the order arrives too late for the main print run.
Offprints are normally despatched within 3 weeks of publication of the issue in which the paper appears. Please contact the publishers if offprints do not arrive: however, offprints are sent by surface mail, so overseas orders may take up to 6 weeks to arrive. Electronic offprints are sent to the first author at his or her first e-mail address on the title page of the paper, unless advised otherwise; please therefore ensure that the name, address, and e-mail address of the corresponding author are clearly indicated on the manuscript title page if he or she is not the first author of the paper.
Copyright Information
Papers accepted must be licensed for publication in the Journal and either an Exclusive Licence Form (ELF) or Open Access Exclusive Licence Form (OOF) (please see OnlineOpen below) must accompany every accepted paper. Authors will be required to license copyright in their paper to Blackwell Publishing. Copyright licensing is a condition of publication, and papers will not be passed to the publisher for production unless copyright has been licensed. To assist authors, an appropriate exclusive license form will be supplied by the Editorial Office. Alternatively, authors may like to download a copy of the appropriate form from the journal website at: http://www.blackwellpublishing.com/pdf/BJCP_ELF.pdf
Online Open
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley InterScience, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see: http://www3.interscience.wiley.com/authorresources/onlineopen.html#OnlineOpen_Terms.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://secure.interscience.wiley.com/funded_access.html
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Authors' checklist
Authors should ensure that they have provided the following information, when appropriate:
1. A title page
2. A title of no more than 150 characters.
3. “What this paper adds” statement (for original papers and short reports)
4. A structured abstract of no more than 250 words.
5. 95% confidence intervals (CI) on differences between major end points.
6. Some numerical data in the abstract, including 95% CIs, when appropriate.
7. Details of precision, accuracy, sensitivity, and specificity for drug/metabolite assays.
8. A statement of ethics committee approval and subject consent.
9. Acknowledgement of financial and other support.
10. A statement of approval of all authors.
11. Preprints of relevant unpublished papers.
The BJCP Prize
The British Pharmacological Society will award an annual prize of £1000 for the best paper published in the print version of the British Journal of Clinical Pharmacology during a calendar year. Those eligible will be Specialist Registrars in Clinical Pharmacology and Therapeutics registered for Higher Medical Training in the UK and the Republic of Ireland and those in comparable training schemes elsewhere. On acceptance of a manuscript the authors will automatically, as part of the Manuscript Central system, be sent a reminder about the BJCP prize and will be invited to fill in an application form, giving information about the provenance of the work and the precise role played by the potential award winner. The judges will be the Editors of the Journal, but they may call for expert assistance in making their decision, which will be final.
Editorial Board
Editor-in-Chief
J. M. Ritter
European Editors
A. Cohen
Y. Loke
Australasian Editor
A. Somogyi
North American Editor
L.D. Lewis
Reviews Editor
A. Ferro
Executive Editorial Board
E. Baker, London
R. Bies, Pittsburgh
T. Blaschke, California
A. de Boer, Utrecht
B.M.Y. Cheung, Birmingham
H. Chrystyn, Bradford
D. Flockhart, Indianapolis
A.S. Gross, Sydney
E. Lee, Singapore
R. MacAllister, London
A. McLachlan, Sydney
J. McLay, Aberdeen
A. Mangoni, Aberdeen
U. Martin, Birmingham
G. Mikus, Heidelberg
P. Minuz, Verona
A. H. Morice, Hull
K. O’Shaughnessy, Cambridge
J. Posner, London
A. Rostami-Hodjegan, Sheffield
M. Schachter, London
R. F. Schäfers, Essen
J.G. Shin, Busan
E. Szabadi, Nottingham
O. von Richter, Darmstadt
J.B. Warren, London
International Editorial Board
L. Bertilsson, Stockholm
S.E. Clarke, Welwyn
J. Drewe, Basel
H.-G. Eichler, Vienna
S. Evans, London
A. G. Frauman, Melbourne
W. Haefeli, Heidelberg
H. Halkin, Tel Aviv
I. P. Hall, Nottingham
A. Johnston, London
F. Kamali, Newcastle upon Tyne
J. R. Laporte, Barcelona
J.O. Miners, Adelaide
J.-L. Montastruc, Toulouse
M. E. de Moraes, Ceara
D. R. Newell, Newcastle-upon-Tyne
O.O. Simooya, Kitwe
J. Slattery, Edinburgh
A. J. Smith Newcastle, Australia
T. Stephenson, Nottingham
B. H. C. Stricker, Rotterdam
H. Tajerzadeh, Tehran
S. Thomas, Newcastle upon Tyne
G. Velo, Verona
R. Weinshilboum, Minnesota
A. Wood, New York
H Yamazaki, Tokyo
P. Ylitalo, Tampere
H. H. Zhou, Changsha
Reviews Board
N. Cranswick, Melbourne
M. Curtis, London
R. Donnelly, Derby
G. Isbister, Newcastle
M. Lennard, Sheffield
D. Liew, Melbourne
J. Martin, Brisbane
T. O'Brien, Melbourne
M. Pirmohamed, Liverpool
J. Ritter, London
M. Schachter, London
D. Waller, Southampton
Chairman, Clinical Section of BPS
P. R. Jackson
Vice-President, Clinical Section of BPS
D. Williams
Honorary Treasurer
D. S. McQueen
| 
